Patient engagement in medical research is a priority for the pharmaceutical industry; however, patient involvement in publications is rare.
At this year’s ISMPP European meeting, a panel of Open Pharma members discussed open access, preprints and post-publication peer review, and the possibility of utilizing these tools to make the publishing of pharmaceutical research faster and more transparent.
We aimed to gain insight into the publishing industry’s perspective on new innovations in the field, as their collaboration will be key to implementing changes.
Featuring the whodunit on the demise of Beall’s list, The Royal Society’s ORCID mandate and how authors and reviewers have responded to PeerJ’s optional open peer review. Who killed Beall's list? via The Chronicle of Higher Education A review of the prime suspects in the demise of Beall’s list, and a discussion on where open … Continue reading Weekly digest: the latest news on topics important to Open Pharma
Summary report from the Open Pharma workstream meetings in July
The Franciscan philosopher Roger Bacon (c1214-1294), who some regard as the father of modern science, argued in his great text Opus Majus that there were four sources of ignorance. Frail and unsuited authority The influence of custom The opinion of the unlearned crowd The concealment of our ignorance in a display of apparent wisdom I … Continue reading Roger Bacon on ignorance and peer review